key: cord-1005614-5u61z0cj
authors: Pang, Wentai; Yang, Fengwen; Zhao, Yubin; Dai, Erhei; Feng, Jihong; Huang, Yuhong; Guo, Yongming; Zhou, Shengyuan; Huang, Ming; Zheng, Wenke; Ma, Jiang; Li, Hong; Li, Qing; Hou, Lijuan; Zhang, Shuo; Wang, Hui; Liu, Qingquan; Zhang, Boli; Zhang, Junhua
title: Qingjin Yiqi granules for post‐COVID‐19 condition: A randomized clinical trial
date: 2022-04-13
journal: J Evid Based Med
DOI: 10.1111/jebm.12465
sha: f62e04bcdfcd91940f02da412ed2396f9afc82fc
doc_id: 1005614
cord_uid: 5u61z0cj

OBJECTIVE: To evaluate the effectiveness and safety of Qingjin Yiqi granules (QJYQ) on post‐COVID‐19 condition (PCC). METHOD: Patients who met the inclusion criteria were randomly assigned to two groups, the QJYQ group received QJYQ combined with standard rehabilitation treatments (SRTs) and the control group only received SRTs. The treatment course was 14 days. The primary outcomes were modified Medical Research Council (mMRC) scale and Borg scale, while the secondary outcomes included symptoms score and 6‐minute walking distance (6MWD). The safety outcome was the incidence of adverse events. RESULTS: A total of 388 patients with PCC were enrolled and randomly assigned to the QJYQ group (n = 194) and the control group (n = 194). Compared to the controls, the mMRC scale was improved in the QJYQ group, which was better than that of the control group [β (95%CI): –0.626 (–1.101, –0.151), p = 0.010]. A significant improvement in Borg scale was also observed in the QJYQ group compared to the control group [β (95%CI): –0.395(–0.744, –0.046), p = 0.026]. There was no statistically significant difference in symptoms score and 6MWD between the two groups (p = 0.293, p = 0.724). No treatment‐related adverse events were observed in either group. CONCLUSIONS: QJYQ can bring benefits to patients with PCC, mainly in the improvement of breathlessness and fatigue.

approximately more than 200 million patients with post-COVID-19 condition (PCC), 5, 6 of which over 90% suffered from persistent symptoms, including fatigue (53.1%−80%), breathlessness (43.4%−53%), anxiety (14.6%−23%), and insomnia (26%−30.8%), [7] [8] [9] [10] [11] substantially reducing the quality of life. 12, 13 For about two years, global researchers have made great achievements in vaccines and drugs, which are powerful weapons for fighting against COVID-19. 14, 15 However, for patients with PCC, there was lack of new treatment. In China, there were several guidelines for the rehabilitation of patients with PCC, 16, 17 where respiratory training as well as traditional Chinese therapies including herbal medicine, acupuncture, traditional exercise (e.g., Baduanjin) were recommended. 18 Qingjin Yiqi granules (QJYQ) is a new prescription for patients with Patients in Hebei and Tianjin, and has been widely used in clinical practice. 16 In order to provide more clinical evidence on the effectiveness and safety of QJYQ, a randomized clinical trial was carried out. 

Participants were recruited from Shijiazhuang People's Hospital and Shijiazhuang Fifth Hospital, who were hospitalized at the two hospitals during the treatment period. Patients who met the discharge criteria were transformed into the rehabilitation ward, where the patients were candidates for this study. Eligible participants were randomly divided into the QJYQ group and the control group in a 1:1 ratio.

Eligible participants were mild, ordinary, or severe COVID-19 patients who met the discharge criteria according to the Guidelines for the Diagnosis and Treatment of COVID-19 (trial version 8): normal temperature for more than 3 days; significant improvements in respiratory symptoms; substantial enhancements of acute exudative lesions on chest radiography; two consecutive negative results of RT-PCR tests with at least a 1-day interval between tests. 19 Exclusion criteria were as follows: chronic lung diseases (e.g., chronic obstructive pulmonary disease, interstitial lung disease); previous history of pulmonary surgical intervention; severe clinical condition (e.g., heart failure, stroke); severe chronic disease (e.g., liver cirrhosis, malignant tumors); allergic constitution or allergic to QJYQ; pregnant or breast feeding women.

All participants received standard rehabilitation treatments (SRTs), and Baduanjin exercise, twice a day. 20 Participants in the QJYQ group took QJYQ orally with a dose of 10 g twice daily for 14 days. Any other herbal medicines were prohibited in either group.

The primary outcomes were the modified Medical Research Council (mMRC) scale and the Borg scale. The mMRC was used to access breathlessness 21, 22 and the Borg scale was employed to evaluate perceived exertion and fatigue. 23 Outcomes were detected and assessed at baseline, 7 days, and 14 days after randomization.

The secondary outcomes were the 6-minute walking distance (6MWD) and the symptoms score. 24 The symptoms score was the sum of each symptom score, which covered cough, expectoration, pharynx ministry unwell, fatigue, breathlessness, chest distress, chest pain, body pain, palpitation, dysphoria, headache, dizziness, insomnia, hair loss, hidrosis, decreased appetite, constipation, diarrhea, smell disorder, and taste disorder. The degree of each symptoms varied from 0 to 3, 0 = no symptom, 1 = mild, 2 = ordinary, 3 = severe.

The safety outcome was treatment-related adverse events.

Treatment-related adverse events involved symptoms and abnormal liver and renal function that were counted as "normal to abnormal" or "abnormal increase". [25] [26] [27] The correlation between adverse events and treatment was assessed by clinical investigators.

Statistical analysis was performed by R software, following the intention to treat (ITT) principle with the mean imputation applied for missing data. Exploratory subgroup analyses of each efficacy outcomes were performed according to gender, age, and comorbidities.

Continuous variables (e.g., age, height, weight) were expressed as mean ± standard error of the mean (SEM), which were compared by the Student's t-test (normally distributed variables) or the Mann-Whitney test (variables without normal distribution). Categorical variables (e.g., gender, symptoms) were presented as counts and percentages, which were compared by the chi-square test. The comparison of efficacy between two groups was conducted by generalized estimating equation (GEE) analyses with the results displayed as β and 95% confidence interval (CI). Statistical tests were two-sided, and the significance level was set at α = 0.05. There was no statistically significant difference between the two groups in the baseline characteristics (Tables 1 and 2 ).

Participants in the QJYQ group exhibited remarkable improvements on both primary outcomes compared with the control group ( Table 3 ). The mMRC scale was illustrated in Figure 2A . In the subgroup analyses of symptoms score and 6MWD, neither the QJYQ group nor the control group showed statistically significant differences in all subgroups (Figures 6 and 7 ).

There was no death or serious adverse event that occurred in either group. Besides, no "abnormal increase" of liver and renal function and no "normal to abnormal" of total bilirubin (TBIL), creatinine (Cr) and blood urea nitrogen (BUN) was observed in both groups. It was found that a total of 19 participants experienced "normal to abnormal" of alanine transaminase (ALT), 9 of them came from the QJYQ group and 10 of them belonged to the control group. Twelve participants were observed to undergo "normal to abnormal" of aspartate aminotransferase (AST), with 4 from the QJYQ group and 8 from the control group.

None of the abnormalities in ALT and AST was considered to be related to QJYQ and SRTs by the assessment of clinical investigators.

The Note: Data are mean ± SEM. QJYQ = Qingjin Yiqi granules; 6MWD = 6-minute walking distance.

Research Council (mMRC) scale. Subgroup analyses were performed on the basis of gender, age, and comorbidities. Data of mMRC scale at baseline, 7 days, and 14 days after randomization were expressed as mean ± standard error of the mean; the effect estimates were represented as β and 95% confidence interval F I G U R E 5 Subgroup analyses of Borg scale. Subgroup analyses were performed on the basis of gender, age, and comorbidities. Data of Borg scale at baseline, 7 days, and 14 days after randomization are expressed as mean ± standard error of the mean; the effect estimates were represented as β and 95% confidence interval F I G U R E 6 Subgroup analyses of symptoms score. Subgroup analyses were performed on the basis of gender, age, and comorbidities. Data of symptoms score at baseline, 7 days, and 14 days after randomization were expressed as mean ± standard error of the mean; the effect estimates were represented as β and 95% confidence interval

In terms of symptoms score and 6MWD, there was no significant difference between the two groups. The participants in this study, whose conditions were predominantly mild instead of serious. Therefore, the symptoms score and 6MWD in this study were close to normal at baseline. SRTs incorporate respiratory training and Baduanjinhad been proven to exert the effects of improving the symptoms and pulmonary function by prior studies. [28] [29] [30] So, it was difficult to detect the specific add-on effect of QJYQ, especially in a small sample clinical trial.

In this study, common symptoms among participants were breath- The reasons for the low symptoms ratios in this study can be summarized as follows: (1) mutations in SARS-CoV-2 occurred over the last 2 years with different variants causing the different ratio of symptoms; 33, 34 (2) the differences in geographic distribution and climate among each study, also influenced the symptoms; (3) the difference interventions for patients with acute COVID-19 condition is an important factor, which can influence the symptom ratio. TCM was rarely used in other countries, and the utilization rate of TCM in the early stage of COVID-19 pandemic was insufficient in China.

All the patients included in this study received TCM during the acute period of COVID-19, which was an important factor in the reduction of symptoms.

There were several limitations in this study. First, it was an openlabel study without placebo control, rather than the double-blind trial, which might cause selection bias and detection bias. Second, add on design was used based on ethical considerations. As a consequence, the real efficacy of QJYQ might be underestimated. Third, the treatment course was no more than 14 days. So, the data of this study could not find the long-time effectiveness of QJYQ. Trials with long-time followup were warranted.

The results of this study provided evidence that QJYQ is a safe Chinese herbal medicine which can bring benefits to patients with PCC. Large sample, strictly designed, randomized clinical trials are still needed to provide more high-quality evidence for the long-term effect of QJYQ for PCC. 

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol

World Health Organization. 2019-nCoV outbreak is an emergency of international concern

World Health Organization. WHO Coronavirus (COVID-19) Dashboard

World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus

Long-term follow-up of recovered patients with COVID-19

Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19

Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19

Post-COVID-19 syndrome (long haul syndrome): description of a multidisciplinary clinic at Mayo Clinic and characteristics of the initial patient cohort

SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection

Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China

An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines (Basel)

Immunological considerations for COVID-19 vaccine strategies

Hebei administration of traditional Chinese medicine, rehabilitation guidelines of integrated medicine for COVID-19 patients in Hebei Province

National Health Commission of the People's Republic of China. Rehabilitation guidelines for discharged COVID-19 patients (Trial Version)

Traditional Chinese medicine in COVID-19

National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (Trial Version 8)

Characteristic of clinical studies on Baduanjin during 2000-2019: a comprehensive review

Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD

Preventive effects of Qingfei Yihuo capsules on air pollution associated exacerbation of chronic obstructive pulmonary disease: a single-blind, randomized, controlled trial

Psychophysical bases of perceived exertion

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test

Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study

Northwell nephrology COVID-19 research consortium. Outcomes among patients hospitalized with COVID-19 and acute kidney injury

Long-term effects of COVID-19 on kidney function

Effect of a respiratory training program using wind instruments on cardiopulmonary function, endurance, and quality of life of elderly women

The effects of 12 weeks of step aerobics training on functional fitness of elderly women

The effects of Baduanjin exercise on fatigue and quality of life in patients with heart failure: a randomized controlled trial

Persistent post-COVID-19 syndrome in hemodialyzed patients-a longitudinal cohort study from the north of Poland

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta)

Changing features of COVID-19: characteristics of infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) variants in Southern Italy

Qingjin Yiqi granules for post-COVID-19 condition: a randomized clinical trial